Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Phala Network (PHA) To Rally Higher? Key Fractal Pattern Signals Potential Upside Move

Phala Network (PHA) To Rally Higher? Key Fractal Pattern Signals Potential Upside Move

CoinsProbeCoinsProbe2025/08/21 08:00
By:Nilesh Hembade

Date: Thu, Aug 21, 2025 | 06:45 AM GMT

The cryptocurrency market is rebounding from the recent dip as Ethereum (ETH) reclaims $4,300, notching a 3% daily gain. This strength has carried into the broader altcoin market, with Phala Network (PHA) now showing early signs of a potential breakout.

PHA climbed 4% in the last 24 hours, and its price structure is beginning to resemble a bullish fractal pattern recently confirmed in Bio Protocol (BIO).

Phala Network (PHA) To Rally Higher? Key Fractal Pattern Signals Potential Upside Move image 0 Source: Coinmarketcap

PHA Mirrors BIO’s Breakout Structure

BIO’s chart has become a valuable reference point for traders. Earlier this year, BIO broke out of a classic falling wedge pattern—a bullish reversal formation. After consolidating beneath a red-marked resistance zone, the token powered higher, reclaiming multiple resistance levels and ultimately rallying by an impressive 124%.

Phala Network (PHA) To Rally Higher? Key Fractal Pattern Signals Potential Upside Move image 1 BIO and PHA Fractal Chart/Coinsprobe (Source: Tradingview)

PHA appears to be walking the same path.

It has also completed a breakout from a falling wedge structure and is now trading just below its immediate red resistance zone at $0.13, currently priced around $0.1186.

What’s Next for PHA?

If the fractal continues to play out, a successful breakout above $0.13 could serve as the trigger for a stronger rally. From there, PHA could target the next resistance levels at $0.1625 and $0.2058, which would represent a potential 72% upside from current prices.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market